Serum protein profiling in diffuse large B-cell lymphoma.

Jacques Riby, James Mobley, Jianqing Zhang, Paige M Bracci, Christine F Skibola

Proteomics. Clinical applications 2016 Nov

filter terms:

The aim of this pilot study was to conduct a nontargeted exploratory proteomics profiling analysis on sera obtained from patients diagnosed with diffuse large B-cell lymphoma (DLBCL) with the goal of identifying disease-specific biomarkers. Sera from 87 participants (57 chemotherapy-naïve diffuse DLBCL patients, 30 controls frequency-matched by age group and World Health Organization (WHO) BMI categories) that were part of a large San Francisco Bay Area case-control study of non-Hodgkin lymphoma were analyzed by liquid chromatography combined with tandem mass spectrometry. Thirty-five proteins (p-adjusted <0.05) were identified as differentially abundant between the DLBCL patients at various disease stages as compared to the controls. Of these, five proteins were randomly selected for further confirmation by ELISA: adiponectin (AdipoQ), cluster of differentiation 14 (CD14), heparin sulfate proteoglycan core protein (HSPG2), extracellular matrix 1 (ECM1), and alpha-1-antichymotrypsin (ACT). These proteins were statistically significantly elevated by 68.8, 37.0, 61.6, 68.0, and 32.0%, respectively, in DLBCL patient sera as compared to controls. These preliminary data when combined with other cancer-related data regarding these proteins warrant continued research in clinical and large prospective studies to clarify the role for these biomarkers in DLBCL pathogenesis and/or prognosis. © 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Citation

Jacques Riby, James Mobley, Jianqing Zhang, Paige M Bracci, Christine F Skibola. Serum protein profiling in diffuse large B-cell lymphoma. Proteomics. Clinical applications. 2016 Nov;10(11):1113-1121